RT Journal Article
SR Electronic
T1 Physician Perceptions of Surveillance: Wearables, Apps, and Bots for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.26.21256102
DO 10.1101/2021.04.26.21256102
A1 Alexandra R. Linares
A1 Katrina A. Bramstedt
A1 Mohan M. Chilukuri
A1 P. Murali Doraiswamy
YR 2021
UL http://medrxiv.org/content/early/2021/04/28/2021.04.26.21256102.abstract
AB Objective To characterize the global physician community’s opinions on the use of digital tools for COVID-19 public health surveillance and self-surveillance.Methods Cross-sectional, random, stratified survey done on Sermo, a physician networking platform, between September 9-15, 2020. We aimed to sample 1,000 physicians divided among the USA, EU, and rest of the world. The survey questioned physicians on the risk-benefit ratio of digital tools, as well as matters of data privacy and trust.Results The survey was completed by 1004 physicians with a mean (SD) age of 49.14 (12) years. Enthusiasm was highest for self-monitoring smart watches (66%) and contact tracing apps (66%) and slightly lower (48-56%) for other tools. Trust was highest for health providers (68%) and lowest for technology companies (30%). Most respondents (69.8%) felt that loosening privacy standards to fight the pandemic would lead to misuse of privacy in the future.Conclusion The survey provides foundational insights about how physicians think of surveillance. Collaborations between public health and technology researchers to strengthen evidence of effectiveness and build public trust may be useful.Competing Interest StatementSermo, a global physician survey platform, provided data sharing. The study authors have no financial ties to Sermo. PMD has received research grants and/or advisory/speaking/board fees from health and technology companies; PMD is a co-inventor on patents relating to diagnostics and wearables; PMD owns shares in several companies. KAB owns a bioethics consulting company (AskTheEthicist, LLC) with industry clients involved in immunology and COVID-19; however, none of her clients were involved in this project. MMC received advisory fee from Eisai for an unrelated project. AL has no conflicts to disclose.Funding StatementThe authors received no external funding support for these analyses and have no financial ties to Sermo. Sermo provided the platform but was not involved in data interpretation, manuscript preparation, or decision to submit.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was deemed as exempt research by Duke University Medical Center's Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request.